Molecule Holdings Inc. Announces Issuance of Cease Trade Order, Application for Partial Revocation Order, and Provides Update on Debenture Amendments and Financing

In This Article:

LANDSDOWNE, ON, March 7, 2024 /CNW/ - Molecule Holdings Inc. (CSE: MLCL) ("Molecule" or the "Company"), a Canadian craft-focused cannabis beverage production company, today announces that on March 5, 2024, the Ontario Securities Commission (the "OSC"), as principal regulator of the Company, issued on a "failure to file" cease trade order ("CTO") prohibiting the trading by any person or company of any securities of the Company in Canada, except pursuant to limited exceptions under the CTO.

The CTO was issued as a result of the Company's delay in filing its annual financial statements, management's discussion and analysis and related officer certifications for the year ended October 31, 2023 (collectively, the "Annual Filings") as required under Parts 4 and 5 of National Instrument 51-102 – Continuous Disclosure Obligations and pursuant to National Instrument 52-109 – Certification of Disclosure in Issuer's Annual and Interim Filings. As disclosed in the Company's prior press releases, the interim financial statements, management's discussion and analysis and related officer certifications for the three and nine months ended July 31, 2023 (the "Interim Filings") were late-filed as a result of a contractual dispute between the Company and the financial services company that assisted the Company with finance-related consulting services (the "Dispute"). The delayed filing of the Interim Filings, as well as the onboarding of the two new independent consultants (together, the "Consultants") currently providing the Company with financial, accounting and bookkeeping services as a result of the Dispute, has caused an associated delay in the preparation and audit of the Annual Filings.

The Company regrets this unnecessary delay in filing and the inconvenience to shareholders and is working with the Consultants and its auditors to file the Annual Filings as soon as possible. It is currently expected that the Annual Filings will be completed prior to the end of May.

The CTO will remain in place until such time as it is fully revoked following the filing of the Annual Filings by the Company, in accordance with National Policy 11-207 – Failure-to-File Cease Trade Orders and Revocations in Multiple Jurisdictions. However, the Company intends to file a partial revocation application (the "Application") with the OSC to allow the Company to complete the Debenture Amendments and the Financing (each as defined under the heading 'Corporate Update' below) during the CTO, as further described under the 'Partial Revocation Application' heading below.